BioMimetic Therapeutics, Inc. | 2005 [and prior] Press Releases
BioMimetic Therapeutics Announces FDA Approval of GEM 21S®
Growth-factor Enhanced Matrix for the Treatment of Periodontally-related Bone Defects
Nov. 21, 2005
|
|
|
BioMimetic Therapeutics Appoints Larry W. Papasan and James G. Murphy to its Board of Directors
Oct. 12, 2005
|
|
|
BioMimetic Pharmaceuticals Strengthens Senior Leadership Team
July 13, 2005
|
|
|
BioMimetic Pharmaceuticals, Inc. Closes Series B Venture Funding
May 21, 2003
|
|
|
BioMimetic Pharmaceuticals Raises Additional $11.8 Million in Equity Financing
May 18, 2005
|
|
|
BioMimetic Pharmaceuticals Raises $25.7 Million in Series C Financing
Nov. 4, 2004
|
|
|
BioMimetic Pharmaceuticals' Receives Approvable Recommendation from FDA Advisory Panel for GEM 21S®
July 15, 2004
|
|
|
BioMimetic Pharmaceuticals Announces Additions to Senior Management Team
Feb. 12, 2004
|
|
|
Orthovita and BioMimetic Enter into a Supply Agreement
Aug. 21, 2002
|
|
|
BioMimetic Pharmaceuticals, Inc. receives investment from Novo A/S
June 25, 2001
|
|
|
BioMimetic Pharmaceuticals, Inc. Raises $6.5 Million in Venture Funding
May 17, 2001
|
|
|
BioMimetic Pharmaceuticals, Inc. Signs Agreements with Harvard Medical School and ZymoGenetics
June 5, 2001
|
|
|
| 
